RECOMBINANT STRAIN OF VV-GMCSF-S-Lact VACCINIA VIRUS, WITH ONCOLYTIC ACTIVITY, PRODUCING GRANULOCYTOR-MACROPHAGAL COLONY-STIMULATING HUMAN FACTOR AND SECRETED FORM OF LACTAPTIN ONCOTOXIC PROTEIN Russian patent published in 2017 - IPC C12N7/01 C12N15/27 C12N15/12 

FIELD: biotechnology.

SUBSTANCE: characterised recombinant strain VV-GMCSF-S-Lact is constructed on the basis of the vaccinia virus L-IVP strain, containing deletions of fragments of viral thymidine kinase and growth factor genes with integrated granulocyte-macrophagal colony-stimulating factor (GM-CSF) with structure corresponding to human GM-CSF matrix RNA cDNA in the central part of the viral thymidine kinase gene; and the secreted S-Lact lactaptin gene, encoding a human cappase-casein fragment of 23-134 a.o. with "stitching" to its N-terminus of the GM-CSF signal peptide (MWLQSLLLLGTVACSIS), in the left end region of the viral genome. The human GM-CSF gene is expressed under the control of the natural promoter P7.5k of the vaccinia virus and produces the secreted form of a biologically active human GM-CSF in mammalian cells. The S-Lact gene is expressed under the control of the synthetic VACV promoter P7.5synth and produces the secreted oncotoxic protein lactaptin.

EFFECT: strain has targeted oncolytic activity against human breast cancer cells in vitro and in vivo and is deposited in SVC of viral infections pathogens and rickettsiosis of FBIS SSC VB Vector under the number V-690.

6 dwg, 1 tbl, 5 ex